Acutus Medical, Inc. (AFIB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acutus Medical, Inc. (AFIB) trades at $0.00 with AI Score 44/100 (Weak). Acutus Medical, Inc. is focused on developing and commercializing tools for catheter-based ablation procedures to treat arrhythmias. Market cap: 9K, Sector: Healthcare.
Last analyzed: Mar 15, 2026Acutus Medical, Inc. (AFIB) Healthcare & Pipeline Overview
Acutus Medical, Inc. specializes in developing and marketing advanced cardiac ablation tools for arrhythmia treatment, including mapping and diagnostic catheters. With a focus on innovation, the company addresses a global market for electrophysiology solutions, facing competition from established medical device manufacturers in the healthcare sector.
Investment Thesis
Investing in Acutus Medical presents a high-risk, high-reward scenario. The company's innovative cardiac ablation technologies could drive significant growth if they gain widespread adoption. However, the company's negative profit margin of -56.5% indicates financial instability. Key value drivers include successful commercialization of its product portfolio and expansion into new markets. Growth catalysts include positive clinical trial results and regulatory approvals. Potential risks include intense competition, limited financial resources, and the need for further capital raises. Investors should closely monitor the company's cash burn rate and progress towards profitability.
Based on FMP financials and quantitative analysis
Key Highlights
- Acutus Medical operates in the electrophysiology market, focusing on arrhythmia treatment.
- The company's product portfolio includes diagnostic and ablation catheters.
- Acutus Medical has a negative profit margin of -56.5%, indicating financial challenges.
- The company's gross margin is 11.1%.
- Acutus Medical's beta is -1.19.
Competitors & Peers
Strengths
- Innovative product portfolio in cardiac ablation.
- Specialized focus on arrhythmia treatment.
- Proprietary technology in mapping and ablation systems.
Weaknesses
- Negative profit margin and financial instability.
- Limited market share compared to larger competitors.
- Reliance on further capital raises.
Catalysts
- Upcoming: Regulatory approvals for new products in key markets.
- Ongoing: Clinical trial results demonstrating the efficacy of Acutus Medical's technologies.
- Ongoing: Strategic partnerships with larger medical device companies to expand market reach.
Risks
- Potential: Intense competition from established medical device companies.
- Potential: Regulatory hurdles and approval delays.
- Ongoing: Financial instability and the need for further capital raises.
Growth Opportunities
- Expansion into International Markets: Acutus Medical has the opportunity to expand its presence in international markets, particularly in Europe and Asia. These markets have a growing demand for advanced cardiac ablation technologies. Successful expansion would require regulatory approvals and strategic partnerships with local distributors. This could significantly increase revenue within the next 3-5 years.
- Development of Next-Generation Products: Investing in research and development to create next-generation ablation technologies and mapping systems can provide a competitive edge. This includes developing more precise and efficient ablation catheters and advanced imaging capabilities. Successful innovation could lead to increased market share and higher margins over the next 5-7 years.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with larger medical device companies or acquiring complementary technologies can accelerate growth. Partnerships can provide access to established distribution networks and increased resources for commercialization. Acquisitions can expand the product portfolio and market reach, creating synergies and economies of scale within the next 2-3 years.
- Focus on Clinical Education and Training: Providing comprehensive clinical education and training programs for electrophysiologists can drive adoption of Acutus Medical's products. This includes hands-on training workshops, online resources, and support from clinical specialists. Effective training programs can build brand loyalty and increase product utilization, leading to sustained growth over the next 1-2 years.
- Leveraging Data Analytics and AI: Integrating data analytics and artificial intelligence into its mapping and ablation systems can improve the accuracy and efficiency of procedures. This includes developing algorithms that can identify optimal ablation targets and predict patient outcomes. These advancements can differentiate Acutus Medical's products and attract clinicians seeking advanced solutions within the next 3-5 years.
Opportunities
- Expansion into international markets.
- Development of next-generation products.
- Strategic partnerships and acquisitions.
Threats
- Intense competition from established medical device companies.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
Competitive Advantages
- Proprietary technology in cardiac mapping and ablation.
- Specialized product portfolio focused on arrhythmia treatment.
- Intellectual property protection through patents and trademarks.
About AFIB
Acutus Medical, Inc., founded in 2011 and headquartered in Carlsbad, California, is a medical device company focused on designing, manufacturing, and marketing a range of tools used in catheter-based ablation procedures. These procedures are designed to treat various heart arrhythmias. The company's product portfolio includes access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, and related consoles and accessories. These products are complemented by supporting algorithms and software programs. Acutus Medical aims to improve the safety and effectiveness of cardiac ablation procedures, offering electrophysiologists advanced tools for diagnosing and treating complex arrhythmias. The company operates both in the United States and internationally, targeting hospitals and electrophysiology labs. Despite its innovative product offerings, Acutus Medical faces challenges in a competitive market dominated by larger, more established medical device companies.
What They Do
- Designs and manufactures catheter-based ablation tools.
- Develops diagnostic and mapping catheters for arrhythmia treatment.
- Offers access sheaths and transseptal crossing tools.
- Provides conventional and contact ablation catheters.
- Creates mapping and imaging consoles and accessories.
- Develops supporting algorithms and software programs for cardiac procedures.
Business Model
- Develops and manufactures medical devices for cardiac electrophysiology.
- Sells products directly to hospitals and electrophysiology labs.
- Generates revenue through the sale of catheters, consoles, and accessories.
Industry Context
Acutus Medical operates within the medical device industry, specifically targeting the electrophysiology market. This market is driven by the increasing prevalence of heart arrhythmias such as atrial fibrillation. The competitive landscape includes larger, established players like ARDS and CGHC, as well as smaller, innovative companies. The industry is characterized by technological advancements in catheter ablation techniques and mapping technologies. Growth is fueled by an aging population and increasing demand for minimally invasive cardiac procedures. The global electrophysiology market is expected to continue growing, presenting opportunities for companies with innovative solutions.
Key Customers
- Hospitals with electrophysiology departments.
- Electrophysiology labs and clinics.
- Cardiac electrophysiologists and technicians.
Financials
Chart & Info
Acutus Medical, Inc. (AFIB) stock price: $0.00 (+0.00, +0.00%)
Latest News
-
Reviewing T2 Biosystems (NASDAQ:TTOO) & Acutus Medical (NASDAQ:AFIB)
defenseworld.net · Feb 19, 2026
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Sep 8, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Aug 22, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Aug 14, 2023
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AFIB.
Price Targets
Wall Street price target analysis for AFIB.
MoonshotScore
What does this score mean?
The MoonshotScore rates AFIB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
AFIB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acutus Medical may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Potential for delisting and loss of investment.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the company's capital structure and financing needs.
- Monitor trading volume and price volatility.
- Consult with a financial advisor or legal professional.
- Independent audits of financial statements.
- Experienced management team with relevant industry expertise.
- Clear and transparent communication with investors.
- Positive media coverage and analyst reports.
- Active engagement with shareholders.
AFIB Healthcare Stock FAQ
What does Acutus Medical, Inc. do?
Acutus Medical, Inc. is a medical device company that designs, manufactures, and markets a range of tools used in catheter-based ablation procedures to treat heart arrhythmias. Their product portfolio includes access sheaths, mapping catheters, ablation catheters, and related consoles and accessories. These products are used by electrophysiologists to diagnose and treat complex heart rhythm disorders, aiming to improve the safety and effectiveness of cardiac ablation procedures. The company operates in the United States and internationally, targeting hospitals and electrophysiology labs.
What do analysts say about AFIB stock?
Analyst coverage of Acutus Medical, Inc. is limited due to its OTC listing and small market capitalization. Key valuation metrics are difficult to assess given the company's negative profit margin and financial instability. Growth considerations include the successful commercialization of its product portfolio and expansion into new markets. Investors should closely monitor the company's cash burn rate and progress towards profitability. Due to the stock data pending update, a current analyst consensus is unavailable.
What are the main risks for AFIB?
Acutus Medical, Inc. faces several significant risks. Intense competition from larger, established medical device companies poses a threat to its market share. Regulatory hurdles and approval delays could impede the commercialization of new products. The company's financial instability and reliance on further capital raises create uncertainty about its long-term viability. Additionally, technological obsolescence and the need for continuous innovation are ongoing challenges in the rapidly evolving medical device industry. The OTC listing presents additional risks related to liquidity and transparency.
What are the key factors to evaluate for AFIB?
Acutus Medical, Inc. (AFIB) currently holds an AI score of 44/100, indicating low score. Key strength: Innovative product portfolio in cardiac ablation.. Primary risk to monitor: Potential: Intense competition from established medical device companies.. This is not financial advice.
How frequently does AFIB data refresh on this page?
AFIB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AFIB's recent stock price performance?
Recent price movement in Acutus Medical, Inc. (AFIB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative product portfolio in cardiac ablation.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AFIB overvalued or undervalued right now?
Determining whether Acutus Medical, Inc. (AFIB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AFIB?
Before investing in Acutus Medical, Inc. (AFIB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or delayed.
- Analyst opinions may not be widely available due to the company's OTC listing.